Issue 4, 2013

Potent growth inhibitory activity of (±)-platencin towards multi-drug-resistant and extensively drug-resistant Mycobacterium tuberculosis

Abstract

The potent antimycobacterial activity of (±)-platencin is reported. Complete inhibition of Mycobacterium smegmatis growth was observed at MICs of 0.5 μg mL−1 and 0.3 μg mL−1 under aerobic and hypoxic conditions, respectively. Notably, the compound exhibited potent bacteriostatic activities towards Mycobacterium tuberculosis H37Rv (MIC = 2 μg mL−1), multi-drug-resistant M. tuberculosis (MIC = 1 μg mL−1), and extensively drug-resistant M. tuberculosis (MIC = 1 μg mL−1). An overexpression study of the transformants of M. smegmatis revealed that platencin selectively targeted Mt-KasB and modestly inhibited Mt-KasA and Mt-FabH.

Graphical abstract: Potent growth inhibitory activity of (±)-platencin towards multi-drug-resistant and extensively drug-resistant Mycobacterium tuberculosis

Article information

Article type
Concise Article
Submitted
12 Jan 2013
Accepted
31 Jan 2013
First published
01 Mar 2013

Med. Chem. Commun., 2013,4, 720-723

Potent growth inhibitory activity of (±)-platencin towards multi-drug-resistant and extensively drug-resistant Mycobacterium tuberculosis

G. A. I. Moustafa, S. Nojima, Y. Yamano, A. Aono, M. Arai, S. Mitarai, T. Tanaka and T. Yoshimitsu, Med. Chem. Commun., 2013, 4, 720 DOI: 10.1039/C3MD00016H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements